Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30), Zacks reports.
Aldeyra Therapeutics Price Performance
ALDX opened at $6.35 on Friday. Aldeyra Therapeutics has a 1-year low of $2.71 and a 1-year high of $6.92. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The business has a 50 day moving average of $5.61 and a 200-day moving average of $5.42.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Monday, March 3rd.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Read More
- Five stocks we like better than Aldeyra Therapeutics
- How Can Investors Benefit From After-Hours Trading
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Stocks to Buy While Others Stay on the Sidelines
- 3 Ways To Invest In Coffee, Other Than Drinking It
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
